Compare BIO-TECHNE Corp (TECH) vs Ishares Msci Thailand Etf (THD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Ishares Msci Thailand Etf — how do they compare? BIO-TECHNE Corp trades at $71.63 (market cap $11.16B), while Ishares Msci Thailand Etf trades at $73.43. The key difference: BIO-TECHNE Corp pays a 0.45% dividend while Ishares Msci Thailand Etf pays none. Which is the better fit depends on your goals.
| TECH | THD | |
|---|---|---|
Market Cap | $11.16B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $72.12 | $75.05 |
52-Week Low | $43.31 | $55.83 |
Enterprise Value | $11.24B | — |
Dividend Yield | 0.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
THD trades at $73.02, up 0.21% on the day, with a bullish technical outlook supported by moving averages and an upcoming dividend of $1.71 scheduled for June 2026. Recent news highlights its strong performance, with nearly 38% total returns over the past year, driven by exposure to AI hardware plays like Delta Electronics. The stock's momentum is reinforced by positive sentiment from financial media, though key financial ratios remain undisclosed in the provided data.
Outlook is cautiously optimistic due to technical strength and AI-driven growth potential, but risks include vulnerability to profit-taking and macroeconomic factors. Investors should monitor earnings reports for fundamental validation, as current data lacks detailed financial metrics. The stock faces competition and regional economic shifts, requiring careful assessment of future guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Ishares Msci Thailand Etf
THD is a country-specific ETF that tracks the performance of the Thai equity market. It provides broad exposure to Thailand's economy across sectors like electronics, energy, and financials, with top holdings such as Delta Electronics.
Read more on THD →
